Treatment of Ventilator-associated Pneumonia Due to Methicillin-Resistant Staphylococcus aureus (MRSA)

Ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) is a specific sub-population of VAP that requires targeted therapy. Standard or broad-spectrum empirical regimens are not the recommended approach when MRSA is identified.

Clinical Scenario

VAP with confirmed or suspected MRSA aetiology — specifically, methicillin-resistant Staphylococcus aureus identified on sputum culture. This resistance profile defines the population for which targeted antibiotic selection is indicated.

Treatment Approach (Partial)

Evidence strongly recommends specific antibiotic agents active against MRSA over other antibiotics or antibiotic combinations for this indication. The complete regimen — including agent selection, dosing strategy, and course duration — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciw353

We recommend that MRSA HAP/VAP be treated with either vancomycin or linezolid rather than other antibiotics or antibiotic combinations (strong recommendation, moderate-quality evidence).

For patients with VAP, we recommend a 7-day course of antimicrobial therapy rather than a longer duration (strong recommendation, moderate-quality evidence).

View source ↗